.
MergerLinks Header Logo

Announced

Completed

Aztiq and Innobic completed the acquisition of Alvogen for $500m.

Financials

Edit Data
Transaction Value£405m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Private

Cross Border

Majority

Pharmaceuticals

treatment development

pharmaceuticals

United States

Friendly

Single Bidder

Completed

Private Equity

Synopsis

Edit

Aztiq, a healthcare investor, and Innobic, a life sciences company, completed the acquisition of Alvogen, a pharmaceutical company, from CVC Capital Partners and Temasek for $500m. "I would like to take this opportunity to thank the existing shareholders for their great support in the transformation of both Lotus and Adalvo, and at the same time to welcome our new partner Innobic as we look forward to carrying out the essential work of expanding access to medicines to more people who need them. With our vast collective expertise, and the comprehensive geographic networks and solid market intelligence in ASEAN brought by innobic and PTT, I believe that Lotus and Adalvo will have a compelling competitive advantage, enabling both enterprises to support one another and advance their global leadership in their sectors," Robert Wessman, Alvogen Chairman and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US